- Research article
- Open Access
JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs
BMC Cardiovascular Disorders volume 5, Article number: 30 (2005)
Microsomal transfer protein inhibitors (MTPi) have the potential to be used as a drug to lower plasma lipids, mainly plasma triglycerides (TG). However, studies with animal models have indicated that MTPi treatment results in the accumulation of hepatic TG. The purpose of this study was to evaluate whether JTT-130, a unique MTPi, targeted to the intestine, would effectively reduce plasma lipids without inducing a fatty liver.
Male guinea pigs (n = 10 per group) were used for this experiment. Initially all guinea pigs were fed a hypercholesterolemic diet containing 0.08 g/100 g dietary cholesterol for 3 wk. After this period, animals were randomly assigned to diets containing 0 (control), 0.0005 or 0.0015 g/100 g of MTPi for 4 wk. A diet containing 0.05 g/100 g of atorvastatin, an HMG-CoA reductase inhibitor was used as the positive control. At the end of the 7th week, guinea pigs were sacrificed to assess drug effects on plasma and hepatic lipids, composition of LDL and VLDL, hepatic cholesterol and lipoprotein metabolism.
Plasma LDL cholesterol and TG were 25 and 30% lower in guinea pigs treated with MTPi compared to controls (P < 0.05). Atorvastatin had the most pronounced hypolipidemic effects with a 35% reduction in LDL cholesterol and 40% reduction in TG. JTT-130 did not induce hepatic lipid accumulation compared to controls. Cholesteryl ester transfer protein (CETP) activity was reduced in a dose dependent manner by increasing doses of MTPi and guinea pigs treated with atorvastatin had the lowest CETP activity (P < 0.01). In addition the number of molecules of cholesteryl ester in LDL and LDL diameter were lower in guinea pigs treated with atorvastatin. In contrast, hepatic enzymes involved in maintaining cholesterol homeostasis were not affected by drug treatment.
These results suggest that JTT-130 could have potential clinical applications due to its plasma lipid lowering effects with no alterations in hepatic lipid concentrations.
Microsomal triglyceride transfer protein (MTP) is a resident protein in the lumen of endoplasmic reticulum and is primarily responsible for transfer of triglycerides (TG) and other lipids from their site of synthesis in the endoplasmic reticulum into the lumen during the assembly of very low density lipoprotein (VLDL) . VLDL produced by the liver are the major source of LDL in plasma and elevated levels of LDL are associated with the development of atherosclerosis and cardiovascular disease (CVD). Increased total cholesterol and LDL cholesterol (LDL-C) are both considered primary risk factors for atherosclerosis [2, 3]. To reduce CHD risk factors improvements in diet and exercise are primary recommendations however when plasma cholesterol concentrations reach a certain limit drug intervention is necessary. Statins, which are targeted to 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and are used extensively, are effective in lowering LDL-C, and somewhat effective in reducing plasma TG [4, 5]. A number of studies done in the past have indicated that reduction in LDL-C values by using statins can significantly reduce the risk of CHD however a large population of patients still experience a clinical event [2, 4, 5]. Therefore, pharmaceutical companies are continuing to research other drug options to control hypercholesterolemia with the goal of developing a therapy for treating patients with dyslipidemias. Microsomal triglyceride transfer protein inhibitor (MTPi) is one such option. It is believed that blocking MTP will not only reduce plasma total and LDL cholesterol (LDL-C) but also plasma VLDL and TG by affecting the packaging and secretion of VLDL and chylomicrons. Certain animal and human studies [6, 7] have shown that the inhibition of MTP blocks the hepatic secretion of VLDL and the intestinal secretion of chylomicrons. Consequently, this mechanism provides a highly efficacious pharmacological target for the lowering of LDL-C and reduction of postprandial lipemia. These effects could afford unprecedented benefit in the treatment of atherosclerosis and consequent cardiovascular disease. The promise of this therapeutic target has attracted widespread interest in the pharmaceutical industry.
This research study had a primary goal to evaluate whether (JTT-130), an MTPi reduces plasma cholesterol and triglyceride concentrations in male Hartley guinea pigs. Since JTT-130 is mainly targeted to the intestine, another main objective of this study was to evaluate whether this MPTi resulted in less hepatic lipid accumulation compared to other inhibitors [6, 7]. Guinea pigs were used as the animal model for this study because of their similarities to humans in terms of hepatic cholesterol and lipoprotein metabolism. Previous studies done in our laboratory report that guinea pig serve as a good model for evaluating cholesterol lowering drugs [8–10].
Reagents were obtained from the following sources. JTT-130, the MTPi tested was provided by Akros Pharma Inc (Princeton, NJ). Enzymatic cholesterol and TG kits, cholesterol oxidase, cholesterol esterase and peroxidase were purchased from Roche-Diagnostics (Indianapolis, IN). Phospholipid and free cholesterol enzymatic kits were obtained from Wako Pure Chemical (Osaka, Japan). Quick-seal ultracentrifuge tubes were from Beckman (Palo Alto, CA). DL-hydroxy- [3-14C] methyl glutaryl coenzyme A (1.81 GBq/mmol), DL- [5-3H] mevalonic acid (370 GBq/mmol), cholesteryl- [1,2,6,7-3H] oleate (370 GBq/mmol), Aquasol, Liquiflor (toluene concentrate) and [14C] cholesterol were purchased from DuPont NEN (Boston, MA). Oleoyl- [1-14C] coenzyme A (1.8 GBq/mmol) and DL-3-hydroxy-3-methyl glutaryl coenzyme A were obtained from Amersham (Clearbrook, IL). Cholesteryl oleate, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, nicotinamide adenine dinucleotide phosphate (NADP), sodium fluoride, Triton, bovine serum albumin and sucrose were obtained from Sigma Chemical (St. Louis, MO). Aluminum and glass silica gel plates were purchased from EM Science (Gibbstown, NJ).
Diets were prepared and pelleted by Research Diets (New Brunswick, NJ). Isocaloric diets were designed to meet all the nutritional requirements for guinea pigs. The four diets had identical composition except for the type and dose of tested drug as indicated in Table 1. The amount of cholesterol in the diets was adjusted to be 0.08 g/100 g, an amount equivalent to 600 mg/day in the human diet .
Forty male guinea pigs (Harlan Sprague-Dawley, Hills), weighing 250–300 g, were randomly assigned to either a control, low dose of MTPi (LDI), high dose of MTPi (HDI) or an atorvastatin (AT) treatment (n = 10/group) for 4 weeks. Initially, all guinea pigs were fed the control diet for 3 weeks to raise plasma cholesterol concentrations. Two animals were housed per metal cage in a light cycle room (light from 0700–1900 h) and had free access to diets and water. Non-fasted guinea pigs were sacrificed by heart puncture after isoflurane anesthesia. Blood and livers were harvested for analysis and were stored at -80°C for further analysis. All animal experiments were conducted in accordance with U.S. Public Health Service/U.S. Department of Agriculture guidelines. Experimental protocols were approved by the University of Connecticut Institutional Care and Use Committee.
Plasma samples were collected from blood obtained by heart puncture from guinea pigs under anesthesia. A preservation cocktail of aprotonin, phenyl methyl sulfonyl fluoride and sodium azide was added to plasma samples to minimize changes in lipoprotein composition during isolation. Plasma was aliquoted for LCAT and CETP determinations, plasma lipid analysis and lipoprotein isolation.
Lipoproteins were isolated by sequential ultracentrifugation  in a LE-80K ultracentrifuge (Beckman Instruments, Palo Alto, CA). VLDL was isolated at d = 1.006 kg/L at 125,000 g at 15°C for 19 h in a Ti-50 rotor. LDL was isolated at d = 1.019-1.09 kg/L in quick-seal tubes at 15°C for 3 h at 200,000 g in a vertical Ti-65 rotor . LDL samples were dialyzed in 0.9 g/L sodium chloride-0.1 g/L ethylene diamine tetra acetic acid (EDTA), pH 7.2, for 12 h and stored at 4°C for further analysis.
Plasma and hepatic lipids
Plasma samples were analyzed for cholesterol and TG by enzymatic methods . Hepatic total and free cholesterol and TG were determined according to the method by Carr et al.  following extraction of hepatic lipids with chloroform-methanol 2:1. Cholesteryl ester concentrations were calculated by subtracting free from total cholesterol.
VLDL and LDL composition was calculated by determining free and esterified cholesterol , protein by a modified Lowry method , and TG and phospholipids by enzymatic kits. VLDL apo B was selectively precipitated with isopropanol . The number of constituent molecules of LDL was calculated on the basis of one apo B per particle with a molecular mass of 412000 kD. The molecular weights were 885.4, 386.6, 645 and 734 for TG, free and esterified cholesterol, and phospholipids, respectively . LDL diameters were calculated according to Van Heek et al . HDL cholesterol was also determined according to Warnick et al, with a modification, which consisted of using 2 mol/L MgCl2 for precipitation of apo-B containing lipoproteins .
Lecithin Cholesterol Acyltransferase (LCAT) and Cholesterol Ester Transfer Protein (CETP) determinations in plasma
LCAT and CETP activities were determined according to Ogawa & Fielding . Physiological CETP activity was determined without inhibiting LCAT activity by measuring the mass transfer of cholesterol ester between HDL and apo B containing lipoproteins. Samples were incubated at 37°C for 6 h in a shaking water bath and total and free plasma cholesterol and HDL cholesterol were measured. LCAT activity was determined by mass analysis of the decrease in plasma free cholesterol between 0 and 6 h at 37°C. Assays were carried out concurrently with measurements of CETP. Both of these methods have been well-standardized for guinea pig plasma .
Hepatic microsome isolation
Hepatic microsomes were isolated as described previously . Briefly a microsomal fraction was isolated by two 25-min centrifugations at 10,000 g (JA-20 rotor, J2-21) followed by ultracentrifugation at 100,000 g in a Ti-50 rotor at 4°C for 1 hour. Microsomes were resuspended in the homogenization buffer and centrifuged for an additional hour at 100,000 g. After centrifugation, microsomal pellets were homogenized and stored at -70°C.
Hepatic HMG-CoA reductase assay
The activity of microsomal HMG-CoA reductase (E.C. 22.214.171.124) was measured in hepatic microsomes as described by Shapiro et al. . HMG-CoA reductase activity was expressed as pmol of [14C] mevalonate produced per min per mg microsomal protein. Recoveries of [3H] mevalonate ranged from 60–90%.
Hepatic Acyl CoA Cholesteryl Acyltransferase (ACAT) activity
Hepatic ACAT (E.C. 126.96.36.199) activity was measured by the incorporation of [14C] oleoyl CoA in cholesteryl ester in hepatic microsomes by preincubating 0.8–1 mg of microsomal protein per assay with 84 g/L albumin and buffer for microsomal isolation . Recoveries of [3H] cholesteryl oleate were between 70–90%.
Hepatic cholesterol 7α-hydroxylase activity
Cholesterol 7α-hydroxylase (E.C. 188.8.131.52) activity was measured according to the method modified by Jelinik et al . [14C] cholesterol was used as a substrate and delivered as cholesterol-phosphatidylcholine liposomes (1:8 by weight) prepared by sonication. An NADPH-regenerating system (glucose-6-phosphate dehydrogenase, NADP, and glucose-6-phosphate) was included in the assay as a source of NADPH.
One-way analysis of variance (ANOVA) (SSPS for Windows version 12) was used to evaluate significant differences among groups in regards to plasma and hepatic lipids, LDL composition, hepatic enzyme activities and LCAT and CETP activities. The LSD post hoc test was used to evaluate the differences among groups. Data are presented as the mean ± SD. Differences were considered significant at P < 0.05.
Plasma lipids and lipoproteins
No difference in weight gain overtime was observed in guinea pigs fed the different test diets (Fig 1), indicating that animals consumed comparable amounts of their respective test diets. After feeding the test diets for a period of four weeks, blood was isolated and plasma was analyzed for cholesterol and TG concentrations. The two doses of MTPi evaluated, low dose (LDI) and high dose (HDI) decreased plasma total cholesterol values significantly by 19.2% (P < 0.01) as compared to the control animals (Table 2). There was no significant difference between the two doses of MTPi tested. Atorvastatin, which was used as a positive control, led to a significantly robust decrease in plasma total cholesterol values of 46%, which was significantly different (P < 0.01) from the two MTPi doses used. Plasma TG values were also significantly lower in LDI (50.8%) and HDI (45.3%) when compared to their control counterparts whereas atorvastatin (AT) treatment resulted in the maximum decrease of plasma TG (Table 2).
The changes in plasma TC values were mostly due to decreases in the cholesterol carried by LDL. LDL-C was also significantly decreased (24.7% & 26.9%) by the MTPi diets tested. There were no major differences between these two doses for plasma lipid parameters except for VLDL-C, which were significantly higher when compared to the low dose of the drug. No significant differences were observed for HDL-C values with MTPi or with AT (Table 2).
LDL size and composition
No significant effect of MTPi on the number of CE molecules or on the size of LDL particle was found with any of the two doses tested as compared to their control counterparts (Table 3). AT treatment reduced the number of esterified cholesterol molecules (45%) as well as decreased the size of LDL particle (30%) (Table 3).
LCAT and CETP activities
Table 3 also summarizes the activities of these two proteins, which play a major role in the intravascular processing of plasma cholesterol. There were no significant differences in LCAT activity when comparing MTPi or statin groups to the control group. However, HDI decreased the activity of CETP, which was comparable to the atorvastatin treated group (P < 0.01).
Hepatic lipids and enzymes
No significant changes were found in hepatic total cholesterol, free cholesterol, cholesteyl ester or TG values in any of the four treatments (Table 4). Results suggest that MTPi did not lead to lipid accumulation in the liver, as there was no significant difference between the two doses of MTPi tested with control or with atorvastatin group. Similarly no significant changes were observed in any of the three regulatory hepatic enzymes involved, namely CYP7, ACAT and HMG-CoA Reductase (Table 5).
In this study we were able to demonstrate that JTT-130, the MTPi tested has the potential to decrease the prime risk factors of cardiovascular disease, namely plasma TG and LDL-C concentrations in guinea pigs. The novelty of the drug tested is that there was no significant accumulation of lipid in the liver as seen in some other studies done with other MTPi [26, 27].
Drug treatment and hepatic lipids
Previous studies evaluating MTPi have shown increase in the lipid content of the liver [7, 26, 27]. Chandler et al  treated Hep-G2 cells with CP-346086, another MTPi, for a period of two weeks. They reported that in addition to decreasing plasma TC, LDL-C, VLDL-C and TG values, this treatment also increased hepatic and intestinal TG when the MTPi was administered with food and when it was dosed away from meals, only hepatic TG were influenced. In contrast, the major finding of this study is that the MTPi tested did not lead to any fat accumulation in the liver as confirmed by no significant changes found in the hepatic lipid content as compared to their control counterparts. The main reason for these differences between MTPi could be that the main target of JTT-130 was the intestine. Because of this, we speculate that due to MTP inhibition, less TG were transferred to the chylomicron particle being packaged in the intestine. As a result a lower concentration of TG was taken up by the hepatocytes through the chylomicron remnant. Thus the VLDL particles secreted from the liver had lower concentrations of TG molecules due to the major inhibitory effect of the MTPi in the intestine. Because there were no significant changes in hepatic cholesterol concentrations, we did not find any significant differences in hepatic enzyme activities. Similar to the study by Conde et al.  in atorvastatin treated guinea pigs with 0.015% atorvastatin, there were no significant differences in hepatic cholesterol concentrations when compared with a control group. However, significant differences in hepatic esterified cholesterol were observed when guinea pigs were treated with a higher dose of the statin (0.05%) .
Drug treatment and plasma lipids and lipoproteins
Abetalipoproteinemia, a genetic disorder characterized by low plasma cholesterol and TG levels, is caused by a functional deficiency of MTP. Absence of lipid transfer activity in the microsomes of abetalipoproteinemia patients established its pivotal function in lipoprotein assembly. This finding led to the suggestion that MTP inhibition could be used as a possible lipid lowering therapy. Further evidence was obtained from a cell culture study in which researchers  proved that MTP is limiting in the production of apo B containing lipoproteins. Another study  further confirmed this finding using heterozygous MTP knockout mice which had 20% less plasma total cholesterol levels compared to wild type mice fed high fat diets; however, they did not find any significant differences in plasma TG concentrations. In our study, we have demonstrated that animals treated with MTPi had not only lower plasma TC and LDL-C but also significant reductions in plasma TG. It is possible that the VLDL particle secreted by the liver was more readily catabolized and therefore there was less conversion to LDL, which contributed to the hypocholesterolemic effects of the MTPi. Conde et al.  demonstrated that there was a significant reduction in plasma TG in guinea pigs treated with atorvastatin when compared to controls. This was partly explained by lower secretion of VLDL particles and by increases in the LDL receptor , which could have contributed to the faster removal of VLDL particles. A similar mechanism may have taken place with the MTPi. By blocking MTP, JTT-130 reduced the secretion of VLDL particles, and therefore, the formation of LDL in the plasma.
There was a dose response in CETP activity with JTT-130, and in addition, guinea pigs treated with atorvastatin exhibited decreased activity of this transfer protein. The main function of CETP is to contribute to the reverse cholesterol pathway by transferring cholesteryl ester from HDL to the apo B containing lipoproteins . However, this action prolongs the residence time of CE in LDL and increases the possibility of its deposition in the arterial wall. Thus lower CETP activity has been associated with decreased atherogenesis in animal studies . Therefore the lowering of CETP activity by drug treatment can be considered beneficial.
Results from this study indicate that JTT-130 has the potential to reduce the primary risk factors for coronary heart disease. While these results are quite promising, more studies are needed to clarify the possibility of adverse effects including steatorhea, fat malabsorption and fat-soluble vitamin absorption. Although the lipid lowering effects were not as pronounced as those observed with atorvastain, the doses of MTPi used in the current study were lower than the doses of atorvastatin. It is possible that using JTT-130 in combination with statins could reduce the wide array of adverse effects associated with reductase inhibitors . This study also demonstrates that MTP inhibitor which is mainly targeted towards the intestine may open a new avenue for treatment of hyperlipidemic patients who are at high risk for cardiovascular diseases.
acyl CoA cholesteryl acyl transferase
cholesterol ester transfer protein
coronary heart disease
high dose of the inhibitor
3-hydroxy-3methyl glutaryl Conezyme A
lecithin cholesterol acyltransferase
low dose of the inhibitor
microsomal transfer protein
microsomal transfer protein inhibitor
nicotinamide adenenine dinucleotide phosphate
very low density lipoprotein.
Hussain MM, Iqbal J, Anwar K, Rava P, Dai K: Microsomal triglyceride transfer protein: a multifunctional protein. Front Biosci. 2003, 500-506. Suppl 8
National Cholesterol Education Program Expert Panel. Second report of the National Cholesterol Education Program (NCEP) Expert panel on Detection: Evaluation and Treatment of High Blood Cholesterol in Adults; Adult Treatment Panel II. Circulation. 1994, 89: 1329-1445.
Association AH: Heart and Stroke Statistical Update. American Heart Association: 2001. 2001
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med. 1995, 333: 1301-1307. 10.1056/NEJM199511163332001.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med. 1996, 335: 1001-1009. 10.1056/NEJM199610033351401.
Raabe M, Veniant MM, Sullivan MA, Zlot CH, Bjorkegren J, Nielson LB, Wong JS, Hamilton RL, Young SG: Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest. 1999, 103 (9): 1287-1298.
Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, Vincent J, Harwood HJ: CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003, 44: 1887-1901. 10.1194/jlr.M300094-JLR200.
West KL, Fernandez ML: Guinea pigs as models to study the hypercholesterolemic effects of drugs. Cardiovasc Drug Rev. 2004, 22 (1): 55-70.
Conde K, Pineda G, Newton RS, Fernandez ML: Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors in the guinea pig. Biochem Pharmacol. 1999, 58: 1209-1219. 10.1016/S0006-2952(99)00203-8.
Fernandez ML: Guinea pigs as models for cholesterol and lipoprotein metabolism. J Nutr. 2001, 131 (1): 10-20.
Lin ECK, Fernandez ML, McNamara DJ: Dietary fat type and cholesterol quantity interact to affect cholesterol metabolism in guinea pigs. J Nutr. 1992, 122: 2019-2029.
Redgrave TG, Roberts DC, West CE: Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem J. 1975, 65: 42-49. 10.1016/0003-2697(75)90488-1.
Fernandez ML, Wilson TA, Conde K, Vegara-Jimenez M, Nicolosi RJ: Hamsters and guinea pigs differ in their plasma lipoprotein cholesterol distribution when fed diets varying in animal protein, soluble fiber or cholesterol content. J Nutr. 1999, 129: 1323-1333.
Allain CC, Poon LC, Chan CS, Richard W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem. 1974, 20: 47-475.
Carr TP, Anderssen CJ, Rudel LL: Enzymatic determination of triglycerides, free cholesterol and cholesterol in tissue lipid extracts. Clin Biochem. 1993, 26: 39-42. 10.1016/0009-9120(93)90015-X.
Markwell MK, Haas S, Bieber LL, Tolbert NE: A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem J. 1978, 87: 206-210. 10.1016/0003-2697(78)90586-9.
Homquist L, Carlson K, Carlson LA: Comparison between the use of isopropanol and tetramethylurea for the solublization and quantitation of human serum very low density apolipoproteins. Anal Biochem J. 1987, 149: 423-426.
Chapman JM, Mills GL, Ledford JH: The distribution and partial characterization of the serum apolipoproteins in the guinea pig. Biochem J. 1975, 149: 423-36.
Conde K, Vergara-Jimenesz M, Krause BR, Newton RS, Fernandez ML: Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res. 1996, 37: 739-746.
Van Heek M, Zilversmit D: Mechanisms of hypertriglyceridemia in the coconut oil/cholesterol-fed rabbits increased secretion and decreased catabolism of VLDL. Arteriosclerosis Thromb. 1991, 11: 918-927.
Ogawa YFCJ: Assay of cholesterol ester transfer activity and purification of a cholesterol ester transfer protein. Meth Enzymol . 1985, 111: 274-285.
Fernandez ML, Conde K, Vergara-Jimenesz M, Behr T, Abdel-Fatta G: Regulation of VLDL-LDL Apo B metabolism in guinea pigs by dietary soluble fiber. Am J Clin Nutr. 1997, 65: 814-822.
Shapiro DL, Imblum RL, Rodwell VW: Thin-layer chromatographic assay for the HMG-CoA reductase and mevalonic acid. Anal Biochem J . 1969, 31: 383-390. 10.1016/0003-2697(69)90279-6.
Smith JL, de Jersey J, pillay SP, Hardie IR: Hepatic acyl-CoA: cholesterol acyltransferase. Development of a standard assay and determination in patients with cholesterol gallstones. Clin Chim Acta. 1986, 158: 271-282. 10.1016/0009-8981(86)90291-3.
Jelinek DF, Andersson S, Slaughter CA, Russel DW: Cloning and regulation of cholesterol 7a-hydroxylase, the rate limiting enzyme in bile acid biosynthesis. J Biol Chem. 1990, 265: 8190-8197.
Liao W, Hui TY, Young SG, Davis RA: Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J Lipid Res. 2003, 44 (5): 978-985. 10.1194/jlr.M300020-JLR200.
Shiomi M, Ito T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol. 2001, 431 (1): 127-131. 10.1016/S0014-2999(01)01419-4.
Jamil H, Gordon DA, Eustice DC, Brooks CM, Dickson JK, Chen Y, Ricci B, Chu CH, Harrity TW, Ciosek CP, Biller SA, Gregg RE, Wetterau JR: An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells. Proc Natl Acad Sci USA . 1996, 93 (21): 11991-11995. 10.1073/pnas.93.21.11991.
Barter P: CETP and atherosclerosis. Arterioscler Thromb Vasc Biol. 2000, 20 (9): 2029-2031.
Le Goff W, Guerin M, Chapman MJ: Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 2004, 101 (1): 17-38. 10.1016/j.pharmthera.2003.10.001.
Ansell BJ: Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Curr Atheroscler Rep. 2005, 7 (1): 29-33.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2261/5/30/prepub
These studies were supported by Akros Pharma Inc, Princeton, NJ
Authors received funding from Akros Pharma Inc. (Princeton, NJ) to carry out the studies presented in this manuscript.
DA did the assays, wrote the manuscript and participated in the interpretation of data; KLW: assisted in the assays for plasma lipids, CETP and LCAT; TLZ: assisted in the determination of ACAT activity and participated in data interpretation, SS: assisted in taking care of guinea pigs, isolation of microsomes and data interpretation; MVJ assisted in the determination of CYP7 and in data interpretation and MLF designed the experiment, evaluated the results, interpreted the data and participated in manuscript preparation.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Aggarwal, D., West, K.L., Zern, T.L. et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 5, 30 (2005). https://doi.org/10.1186/1471-2261-5-30
- Cholesterol Ester Transfer Protein
- Hepatic Lipid
- Ethylene Diamine Tetra Acetic Acid
- Microsomal Triglyceride Transfer Protein